Jones Day, Skadden, Wilmer Hale act on $5.9 bln Japan-U.S. pharma deal
BY Mari Iwata |
Jones Day has advised Japan’s Astellas Pharma on its $5.9 billion acquisition of U.S. drugmaker Iveric Bio, which was represented by Skadden, Arps, Slate, Meagher & Flom and Wilmer Cutler Pickering Hale and Dorr.